Our study showed that three polymorphisms with low DA activity (InsIns in DRD2rs1799732, DRD4-L allele in DRD4-VNTR, and 9R9R homozygote in DAT1-VNTR) were associated with the SGA treatment-induced risk of developing cardiometabolic disorder parameters (obesity BMI, abdominal obesity, high DBP, and HTG) in patients with a severe mental disorder. This evidence concerns the gene SLC6A3 and psychiatric disorder.